Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Carbone

Showing results (121-130 of 283) with videos related to

Pageof 29
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 27, 2019
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greaterLongjiang She, Huabin Hu, Mengting Liao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2017
Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung CancerPatrick Wald, Xiaokui Mo, Christian Barney, et al.
Lung Cancer (Amsterdam, Netherlands)|October 14, 2021
Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancerMin Li, Chunliu Zhang, Shichao Deng, et al.
Molecular Endocrinology (Baltimore, Md.)|February 6, 2010
Deletion of IGF-I receptor (IGF-IR) in primary osteoblasts reduces GH-induced STAT5 signalingYujun Gan, Yue Zhang, Douglas J Digirolamo, et al.
Clinical Lung Cancer|August 18, 2016
Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims AnalysisTasneem Lokhandwala, Marisa A Bittoni, Robert A Dann, et al.
Clinical Lung Cancer|September 11, 2018
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung CancerDwight H Owen, Lai Wei, Erin M Bertino, et al.
Cancer Research Communications|October 18, 2023
Exogenous Sequences in Tumors and Immune Cells (Exotic): A Tool for Estimating the Microbe Abundances in Tumor RNA-seq DataRebecca Hoyd, Caroline E Wheeler, YunZhou Liu, et al.
The Journal of Clinical Investigation|March 6, 2003
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptorLi Yang, Noboru Yamagata, Rajwardhan Yadav, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancerDavid I Rosenthal, Clifton David Fuller, Mitchell Machtay, et al.
The Journal of Clinical Investigation|December 18, 2025
PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activationZhaojun Qiu, No-Joon Song, Anqi Li, et al.
Pageof 29

Showing results (121-130 of 283) with videos related to

Sort By:
Pageof 29
Lung Cancer (Amsterdam, Netherlands)|October 27, 2019
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greaterLongjiang She, Huabin Hu, Mengting Liao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2017
Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung CancerPatrick Wald, Xiaokui Mo, Christian Barney, et al.
Lung Cancer (Amsterdam, Netherlands)|October 14, 2021
Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancerMin Li, Chunliu Zhang, Shichao Deng, et al.
Molecular Endocrinology (Baltimore, Md.)|February 6, 2010
Deletion of IGF-I receptor (IGF-IR) in primary osteoblasts reduces GH-induced STAT5 signalingYujun Gan, Yue Zhang, Douglas J Digirolamo, et al.
Clinical Lung Cancer|August 18, 2016
Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims AnalysisTasneem Lokhandwala, Marisa A Bittoni, Robert A Dann, et al.
Clinical Lung Cancer|September 11, 2018
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung CancerDwight H Owen, Lai Wei, Erin M Bertino, et al.
Cancer Research Communications|October 18, 2023
Exogenous Sequences in Tumors and Immune Cells (Exotic): A Tool for Estimating the Microbe Abundances in Tumor RNA-seq DataRebecca Hoyd, Caroline E Wheeler, YunZhou Liu, et al.
The Journal of Clinical Investigation|March 6, 2003
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptorLi Yang, Noboru Yamagata, Rajwardhan Yadav, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancerDavid I Rosenthal, Clifton David Fuller, Mitchell Machtay, et al.
The Journal of Clinical Investigation|December 18, 2025
PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activationZhaojun Qiu, No-Joon Song, Anqi Li, et al.
Pageof 29